Abstract：
:Epithelial-to-mesenchymal transition (EMT) determines the most lethal features of cancer, metastasis formation and chemoresistance, and therefore represents an attractive target in oncology. However, direct targeting of EMT effector molecules is, in most cases, pharmacologically challenging. Since emerging research has highlighted the distinct metabolic circuits involved in EMT, we propose the use of metabolism-specific inhibitors, FDA approved or under clinical trials, as a drug repurposing approach to target EMT in cancer. Metabolism-inhibiting drugs could be coupled with standard chemo- or immunotherapy to combat EMT-driven resistant and aggressive cancers.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Ramesh V,Brabletz T,Ceppi Pdoi
10.1016/j.trecan.2020.06.005subject
Has Abstractpub_date
2020-11-01 00:00:00pages
942-950issue
11eissn
2405-8033issn
2405-8025pii
S2405-8033(20)30189-8journal_volume
6pub_type
杂志文章,评审相关文献
Trends in Cancer文献大全abstract：:Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.07.002
更新日期：2018-09-01 00:00:00
abstract：:GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.07.005
更新日期：2019-09-01 00:00:00
abstract：:Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host int...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.11.006
更新日期：2020-12-09 00:00:00
abstract：:The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2015.07.004
更新日期：2015-10-01 00:00:00
abstract：:Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to devel...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2016.07.002
更新日期：2016-08-01 00:00:00
abstract：:Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensiti...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.01.003
更新日期：2020-03-01 00:00:00
abstract：:Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.04.010
更新日期：2020-08-01 00:00:00
abstract：:In a recent article, Bisogno et al. reported in a randomized trial that addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with rhabdomyosarcoma resulted in a significant increase in overall and event-free survival. Although the mechanism of action remains to be fully ...
journal_title：Trends in cancer
pub_type： 评论,杂志文章
doi：10.1016/j.trecan.2019.10.004
更新日期：2019-12-01 00:00:00
abstract：:In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.05.014
更新日期：2020-09-01 00:00:00
abstract：:Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.03.008
更新日期：2017-05-01 00:00:00
abstract：:Nuclear receptors are a family of transcription factors localized in cell nuclei, sensing specific ligands and fine-tuning a variety of cell physiological events. They have been intensively investigated in cancer biology. With their excellent properties of druggability and actionability, nuclear receptors have demonst...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.11.007
更新日期：2020-12-16 00:00:00
abstract：:The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.03.009
更新日期：2018-05-01 00:00:00
abstract：:Cadherins are key components in tissue morphogenesis and architecture, contributing to the establishment of cohesive cell adhesion. Reduced cellular adhesiveness as a result of cadherin dysfunction is a defining feature of cancer. During tumor development and progression, major changes in the glycan repertoire of canc...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.08.003
更新日期：2016-09-01 00:00:00
abstract：:Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.01.003
更新日期：2017-03-01 00:00:00
abstract：:Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.01.010
更新日期：2020-04-01 00:00:00
abstract：:Alternative lengthening of telomeres (ALT) is an enigmatic process that allows certain cancers to maintain telomeres in the absence of telomerase. ALT cancers are frequently defective for ATRX/DAXX, a chaperone complex that deposits histone variant H3.3 at telomeres. We propose that mutations in alpha thalassemia-ment...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.02.003
更新日期：2016-03-01 00:00:00
abstract：:Dendritic cells (DCs) are key orchestrators of immune responses. A specific DC subset, conventional type 1 DCs (cDC1s), has been recently associated with human cancer patient survival and, in preclinical models, is critical for the spontaneous rejection of immunogenic cancers and for the success of T cell-based immuno...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.09.001
更新日期：2018-11-01 00:00:00
abstract：:The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. T...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.03.008
更新日期：2016-05-01 00:00:00
abstract：:The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2017.06.007
更新日期：2017-08-01 00:00:00
abstract：:In recognition of the enormous potential of immunotherapies against cancer, research into the interactions between tumor and immune cells has accelerated, leading to the recent FDA approval of several drugs that reduce cancer progression. Numerous cellular and molecular interactions have been identified by which immun...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2015.12.003
更新日期：2016-01-01 00:00:00
abstract：:TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2020.01.007
更新日期：2020-02-01 00:00:00
abstract：:Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2020.12.003
更新日期：2021-02-01 00:00:00
abstract：:The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title：Trends in cancer
pub_type： 杂志文章
doi：10.1016/j.trecan.2016.01.002
更新日期：2016-02-01 00:00:00
abstract：:The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.12.004
更新日期：2018-02-01 00:00:00
abstract：:Ibrutinib resistance, as a result of coordinated rewiring of signaling networks and enforced tumor microenvironment (TME)-lymphoma interactions, drives unrestrained proliferation and disease progression. To combat resistance mechanisms, we must identify the compensatory resistance pathways and the central modulators o...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.01.004
更新日期：2018-03-01 00:00:00
abstract：:The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2016.03.005
更新日期：2016-04-01 00:00:00
abstract：:For millenia, plants have been a major source of medications against human and animal diseases. In the case of anticancer agents, a significant number of current agents can trace their source back to nominally plant secondary metabolites, with examples being taxol, vinca alkaloids, camptothecin (CPT), and their modifi...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2018.08.002
更新日期：2018-10-01 00:00:00
abstract：:The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genet...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.10.005
更新日期：2017-12-01 00:00:00
abstract：:Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2019.02.009
更新日期：2019-04-01 00:00:00
abstract：:The p90 ribosomal S6 kinase family (RSK1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. The RSKs phosphorylate a range of substrates involved in transcription, translation, cell cycle regulation, and cell survival. Although the RSKs have a h...
journal_title：Trends in cancer
pub_type： 杂志文章,评审
doi：10.1016/j.trecan.2017.03.004
更新日期：2017-04-01 00:00:00
